Jacqueline Yee

1.5k total citations · 1 hit paper
22 papers, 1.2k citations indexed

About

Jacqueline Yee is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Genetics. According to data from OpenAlex, Jacqueline Yee has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 10 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Genetics. Recurrent topics in Jacqueline Yee's work include Diabetes Treatment and Management (10 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (5 papers). Jacqueline Yee is often cited by papers focused on Diabetes Treatment and Management (10 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (5 papers). Jacqueline Yee collaborates with scholars based in United States, Belgium and Canada. Jacqueline Yee's co-authors include Gary Meininger, William Canovatchel, Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock, Min Fu, Masato Kawaguchi, Ujjwala Vijapurkar, Thomas Först and Ronald Goldenberg and has published in prestigious journals such as Gastroenterology, Diabetes Care and Biological Psychiatry.

In The Last Decade

Jacqueline Yee

22 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

2013 404 citations Guntram Schernthaner, Jacqueline Yee et al. Diabetes Care profile →

Peers

Countries citing papers authored by Jacqueline Yee

Since Specialization

Citations

This map shows the geographic impact of Jacqueline Yee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Yee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Yee more than expected).

Fields of papers citing papers by Jacqueline Yee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline Yee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Yee. The network helps show where Jacqueline Yee may publish in the future.

Co-authorship network of co-authors of Jacqueline Yee

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Yee. A scholar is included among the top collaborators of Jacqueline Yee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline Yee. Jacqueline Yee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P0669 Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s Disease 2025 ·Journal of Crohn s and Colitis ·Silvio Danese, Bruce E. Sands, Anita Afzali, Tadakazu Hisamatsu, Alessandro Armuzzi, Douglas C. Wolf, (unknown), Rian Van Rampelbergh, Mobolaji Olurinde, Natalie A. Terry, Jacqueline Yee, Li Huang, (unknown), Geert D’Haens, David T. Rubin, (unknown)	1
2	P0608 Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis 2025 ·Journal of Crohn s and Colitis ·B E Sands, Remo Panaccione, Silvio Danese, Julián Panés, Takashi Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Monica L. Vetter, Li Huang, (unknown), Jessica R. Allegretti, Anita Afzali, David T. Rubin	1
3	P0917 Corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn’s disease: Phase 3 GALAXI 2/3 results through week 48 2025 ·Journal of Crohn s and Colitis ·Julián Panés, Tadakazu Hisamatsu, Alessandro Armuzzi, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Kitty Y. Wan, Zijiang Yang, (unknown), Bruce E. Sands, David T. Rubin	2
4	Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study 2025 ·Gastroenterology ·(unknown), (unknown), Flávio Steinwurz, Silvio Danese, Tadakazu Hisamatsu, Qian Cao, Timothy E. Ritter, Ursula Seidler, Mobolaji Olurinde, Marion Vetter, Jacqueline Yee, Zijiang Yang, Yuhua Wang, Jewel Johanns, Chenglong Han, (unknown), Natalie A. Terry, Bruce E. Sands, Geert D’Haens, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	12
5	DOP060 Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies 2025 ·Journal of Crohn s and Colitis ·Anita Afzali, David T. Rubin, Silvio Danese, Yaser Rayyan, Min Chen, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Jacqueline Yee, Mario Gómez, Kitty Y. Wan, Zijiang Yang, B E Sands, Geert D’Haens	3
6	EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES 2024 ·Gastroenterology ·Remo Panaccione, Silvio Danese, Brian G. Feagan, Geert D’Haens, (unknown), Walter Reinisch, Julián Panés, David T. Rubin, Jane M. Andrews, Tadakazu Hisamatsu, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Kitty Y. Wan, Jacqueline Yee, Bruce E. Sands	22
7	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study 2020 ·Current Medical Research and Opinion ·Žhong Yuan, Frank DeFalco, (unknown), Laura Hester, James Weaver, Joel N. Swerdel, (unknown), Patrick Ryan, Martijn J. Schuemie, R. Qiu, Jacqueline Yee, Gary Meininger, Jesse A. Berlin, Norman Rosenthal	3
8	Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data 2017 ·Cardiovascular Diabetology ·Michael J. Davies, (unknown), Ujjwala Vijapurkar, Jacqueline Yee, Rong Qiu	24
9	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial 2017 ·Diabetes Obesity and Metabolism ·Bruce Neal, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse, Jacqueline Yee, Hsiaowei Deng, Dick de Zeeuw, (unknown)	122
10	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials 2015 ·Current Medical Research and Opinion ·Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel, Gary Meininger	8
11	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus 2014 ·Journal of Diabetes and its Complications ·John Wilding, Lawrence Blonde, Lawrence A. Leiter, Sonia Cerdas, Cindy S.W. Tong, Jacqueline Yee, Gary Meininger	39
12	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone 2014 ·Diabetes Obesity and Metabolism ·Thomas Först, Robert Guthrie, Ronald Goldenberg, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger, Peter Stein	219
13	Achievement of Diabetes-Related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) 2014 ·Canadian Journal of Diabetes ·Vincent Woo, Lawrence Blonde, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger	1
14	Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks 2013 ·Canadian Journal of Diabetes ·Ronald Goldenberg, Thomas Först, Robert D. Guthrie, Jacqueline Yee, Ujjwala Vijapurkar, Gary Meininger, Peter Stein	2
15	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 2013 ·Diabetes Care ·Guntram Schernthaner, JL Gross, J Rosenstock, (unknown), Minghuan Fu, Jacqueline Yee, (unknown), William Canovatchel, Gary Meininger	80
16	An evaluation of the relationship between vitamin d status and quadriceps strength in patients with copd: a cross sectional study 2011 ·British Journal of Sports Medicine ·(unknown), Adrian R. Martineau, Jacqueline Yee, (unknown), Chris Griffiths, Nicola Maffulli, Dylan Morrissey	1
17	Absence of adynamic bone disease in African- Americans with CKD Stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio 2009 ·Clinical Nephrology ·(unknown), Yasser Osman, (unknown), Kayla L. Nguyen, (unknown), Tom Cantor, Marie‐Claude Monier‐Faugere, Jacqueline Yee, Hartmut H. Malluche	7
18	Amyloid-Associated Depression 2008 ·Archives of General Psychiatry ·Xiaoyan Sun, David C. Steffens, Rhoda Au, Marshal F. Folstein, Paul Summergrad, Jacqueline Yee, Irwin H. Rosenberg, D. Mkaya Mwamburi, Wei Qiao Qiu	139
19	Depression, Antidepressants, and Plasma Amyloid β (Beta) Peptides in Those Elderly Who Do Not Have Cardiovascular Disease 2007 ·Biological Psychiatry ·Xiaoyan Sun, D. Mkaya Mwamburi, Kathleen M. Bungay, Jasmin Prasad, Jacqueline Yee, Yu‐Min Lin, (unknown), Paul Summergrad, Marshal F. Folstein, Wei Qiao Qiu	33
20	Executive Dysfunction in Homebound Older People with Diabetes Mellitus 2006 ·Journal of the American Geriatrics Society ·Wei Qiao Qiu, Lori Lyn Price, Patricia L. Hibberd, Jennifer S. Buell, Lauren F. Collins, (unknown), D. Mkaya Mwamburi, Irwin H. Rosenberg, (unknown), Tammy Scott, Richard D. Siegel, Paul Summergrad, Xiaoyan Sun, (unknown), Lixia Wang, Jacqueline Yee, Katherine L. Tucker, Marshal F. Folstein	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact